CNC on NYSE

Centene Corporation

Logo: Centene Corporation Uploaded by Grmike at en.wikipedia, Public domain, via Wikimedia Commons6

American healthcare company

Centene Corporation is an American for-profit healthcare company that serves as an intermediary for government-sponsored and privately insured healthcare programs. Based in Clayton, Missouri, Centene ranked No. 23 on the 2025 Fortune 500.3 Its chief executive is Sarah London (since 2022).1 Its revenue was $145 billion in 2022.1 Its shares trade on NYSE under the symbol CNC.1 Wikipedia text CC BY-SA 4.0

$69.19 down 1.32 (1.87%)Price as of Oct 16, 2026 at 19:58 UTC

Last updated Oct 21, 2026.

Overview

1984Founded1

Compare with Elevance Health, Inc., Humana or The Cigna Group, or pick any stock.

  • TickerCNC on NYSE1
  • Industryhealth care1
  • HeadquartersSt. Louis1
  • Websitewww.centene.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address7700 Forsyth Blvd., St Louis, Mo 631057
  • Filer categoryLarge accelerated filer7
  • LEI549300Z7JJ4TQSQGT3334
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 34398384

Centene Corporation is an American for-profit healthcare company that serves as an intermediary for government-sponsored and privately insured healthcare programs. Based in Clayton, Missouri, Centene ranked No. 23 on the 2025 Fortune 500.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

8.1%Gross margin11
-4.4%Operating margin11
-3.8%Net margin11
20.0%Revenue growth, 202511
-33.4%Return on equity11
0.87×Debt to equity11
$4.3BFree cash flow11

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Total Premium and Service brought in 50% of the revenue Centene Corporation broke down this way in fiscal 2025.

  1. Total Premium and Service$174.6B1150%up 20% from 2024
  2. Health Care, Premium$171.6B1150%up 21% from 2024
Products and services by year
Products and services202320242025
Total Premium and Service$140.1B$145.5B$174.6B
Health Care, Premium$135.6B$142.3B$171.6B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$2.7B
  • Selling, general and admin7¢$12.9B
  • Other costs91¢$159.0B
  • Income tax0¢$51.0M

Out of $174.6B in revenue.11 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending15¢$767.0M
  • Share buybacks9¢$475.0M
  • Kept or used elsewhere76¢$3.8B

Out of $5.1B of cash from operations.11

Financial statements

Revenue1213141511$174.6B in 2025+148% since 2019
0$50.0B$100.0B$150.0B$200.0B2019: $70.4B$70.4B20192020: $103.8B$103.8B2020+48%2021: $118.0B$118.0B2021+14%2022: $135.5B$135.5B2022+15%2023: $140.1B$140.1B2023+3%2024: $145.5B$145.5B2024+4%2025: $174.6B$174.6B2025+20%
Gross profit141511$14.2B in 2025−2% since 2021
0$5.0B$10.0B$15.0B$20.0B2021: $14.5B$14.5B20212022: $16.9B$16.9B2022+17%2023: $17.6B$17.6B2023+4%2024: $17.1B$17.1B2024−3%2025: $14.2B$14.2B2025−17%
Operating income1213141511-$7.6B in 2025
-$10.0B-$5.0B0$5.0B2019: $1.8B$1.8B20192020: $3.1B$3.1B2020+73%2021: $1.8B$1.8B2021−42%2022: $1.3B$1.3B2022−26%2023: $2.9B$2.9B2023+122%2024: $3.2B$3.2B2024+8%2025: -$7.6B-$7.6B2025
Net income1213141511-$6.7B in 2025
-$7.5B-$5.0B-$2.5B0$2.5B$5.0B2019: $1.3B$1.3B20192020: $1.8B$1.8B2020+37%2021: $1.3B$1.3B2021−25%2022: $1.2B$1.2B2022−11%2023: $2.7B$2.7B2023+125%2024: $3.3B$3.3B2024+22%2025: -$6.7B-$6.7B2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.11

Period ending2025-12-312024-12-312023-12-31
Premium and service revenues$174.6B$145.5B$140.1B
Premium tax$20.2B$17.6B$13.9B
Total revenues$194.8B$163.1B$154.0B
Medical costs$157.7B$125.7B$118.9B
Cost of services$2.7B$2.7B$3.6B
Selling, general and administrative expenses$12.9B$12.4B$12.6B
Depreciation expense$590.0M$549.0M$575.0M
Amortization of acquired intangible assets$685.0M$692.0M$718.0M
Premium tax expense$20.5B$17.8B$14.2B
Impairment$7.3B$13.0M$529.0M
Total operating expenses$202.4B$159.9B$151.1B
Earnings (loss) from operations-$7.6B$3.2B$2.9B
Investment and other income$1.6B$1.8B$1.4B
Debt extinguishment$1.0M$0$0
Interest expense-$678.0M-$702.0M-$725.0M
Earnings (loss) before income tax-$6.7B$4.3B$3.6B
Income tax (benefit) expense-$51.0M$963.0M$899.0M
Net earnings (loss)-$6.7B$3.3B$2.7B
Loss attributable to noncontrolling interests$3.0M$11.0M$3.0M
Net earnings (loss) attributable to Centene Corporation-$6.7B$3.3B$2.7B
Basic earnings (loss) per common share (in usd per share)-$13.53$6.33$4.97
Diluted earnings (loss) per common share (in usd per share)-$13.53$6.31$4.95
Basic (in shares)493.1M shares521.8M shares543.3M shares
Diluted (in shares)493.1M shares523.7M shares545.7M shares

Compare Centene Corporation with another company

Corporate structure

Centene Corporation sits at the top of its group. 18 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Centene Corporation

  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Centene Corporation, latest Apr 29, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Centene Corporation, latest Mar 26, 2026 (4 filings since Feb 9, 2022)
  • AQR CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Centene Corporation, latest Feb 13, 2026
  • FMR LLC Filed SCHEDULE 13G/A on Centene Corporation, latest Nov 5, 2025 (6 filings since Feb 9, 2022)
  • NORGES BANK Filed SCHEDULE 13G/A on Centene Corporation, latest Nov 4, 2025 (2 filings since Feb 11, 2025)
  • HARRIS ASSOCIATES L P Filed SCHEDULE 13G/A on Centene Corporation, latest Aug 14, 2025 (2 filings since Nov 14, 2024)
  • BlackRock Filed SCHEDULE 13G/A on Centene Corporation, latest Jul 16, 2025 (6 filings since Feb 3, 2022)
  • Capital World Investors Filed SC 13G/A on Centene Corporation, latest Nov 13, 2024 (4 filings since Feb 11, 2022)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Centene Corporation, latest Feb 14, 2022
  • Centene Corporation Wilmington, Delaware, United States
    • Circle Health Group London, United Kingdom
      • BMI Healthcare Subsidiary · London
        • Alexandra Hospital Subsidiary · Stockport, United Kingdom
      • Albyn Hospital Subsidiary · Aberdeen City, United Kingdom
      • Beardwood Hospital Subsidiary · Blackburn with Darwen, United Kingdom
      • Beaumont Hospital Subsidiary · Bolton, United Kingdom
      • Bishops Wood Hospital Subsidiary · Northwood, United Kingdom
      • Duchy Hospital Subsidiary · Harrogate, United Kingdom
      • Princess Margaret Hospital Subsidiary · Windsor, United Kingdom
      • The Meriden Hospital Subsidiary · Coventry, United Kingdom
      • The Priory Hospital Subsidiary · Birmingham, United Kingdom
    • Fidelis Care Subsidiary · New York City
    • Health Net Subsidiary · Wilmington, Delaware, United States
    • Magellan Health Subsidiary · Scottsdale
    • Bankers Reserve Life Insurance Company of Subsidiary · Wisconsin, United States
    • Envolve Health Subsidiary
    • Human Affairs International of Subsidiary · California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Centene Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.3B11 Dec 31, 2025$4.9B11 Dec 31, 2024−12.3%
Accumulated depreciation$2.2B11 Dec 31, 2025$2.8B11 Dec 31, 2024−20.4%
Property and equipment, net$2.0B11 Dec 31, 2025$2.1B11 Dec 31, 2024−1.5%
Operating-lease assets (leased space)$317.0M11 Dec 31, 2025$359.0M11 Dec 31, 2024−11.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$17.9B11 Dec 31, 2025$14.1B11 Dec 31, 2024+27.2%
Marketable securities, current$2.4B11 Dec 31, 2025$2.6B11 Dec 31, 2024−7.2%
Equity securities at fair value$1.0M11 Dec 31, 2025$14.0M11 Dec 31, 2024−92.9%
Stakes in other companies (equity method)$915.0M11 Dec 31, 2025$851.0M11 Dec 31, 2024+7.5%
Long-term investments$17.0B11 Dec 31, 2025$17.4B11 Dec 31, 2024−2.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$10.8B11 Dec 31, 2025$17.6B11 Dec 31, 2024−38.3%
Intangible assets, net (excluding goodwill)$4.5B11 Dec 31, 2025$5.4B11 Dec 31, 2024−16.3%
Finite-lived intangibles, gross$9.4B11 Dec 31, 2025$9.7B11 Dec 31, 2024−3.4%
Accumulated amortization$4.8B11 Dec 31, 2025$4.3B11 Dec 31, 2024+12.8%
Finite-lived intangibles, net$4.5B11 Dec 31, 2025$5.4B11 Dec 31, 2024−16.3%

Properties, in its own words

We own our corporate office headquarters buildings and land located in St. Louis, Missouri, which are used by each of our reportable segments. We generally lease space in the states where our health plans and claims processing facilities operate. We are required by various insurance and regulatory authorities to have offices in the service areas where we provide benefits.

We believe our current facilities are adequate to meet our operational needs for the foreseeable future.

Item 2 of the 10-K filed Feb 17, 2026.19

The story

Centene was founded by Elizabeth Brinn as Managed Health Services in Milwaukee, Wisconsin, in 1984. After the death of Brinn, the non-profit organization was sold to investors. The proceeds went to the Betty Brinn Foundation, which became a major shareholder in Centene. In 1996, Michael Neidorff joined the company as chief executive.

Centene went public in December 2001. In 2006, the firm acquired US Script, a pharmacy benefits manager. The company later merged US Script with subsidiaries to form its Envolve divisions. In 2011, the firm formed Centurion, a provider of correctional health care services, as a joint venture with MHM Services. In 2018, it acquired MHM Services, including its stake in Centurion. Centene began offering state-run Medicaid programs through Affordable Care Act exchanges in 2014.

In July 2015, Centene announced it would acquire Health Net and Trillium Community Health Plan (serving Oregon). In March 2016, it finalized its acquisition. In September 2017, it announced that it would acquire Fidelis Care, a nonprofit insurer in New York, for US$3.75 billion. In March 2019, it announced plans to acquire WellCare for US$17.3 billion, a deal completed in January 2020. In January 2021, it was announced that it would acquire Magellan Health for $2.2 billion. In January 2022, the acquisition was completed.

In the United Kingdom, Centene began to acquire local healthcare services in 2017. In 2019, Centene, through its subsidiary MH Services, took a 40% stake in Circle Health, as part of a deal which created a national network of over 50 private hospitals. Centene gained full control of Circle Health in July 2021, and sold the business to PureHealth in August 2023.

In early 2021, Operose Health, a UK subsidiary of Centene, took over a group of London practices, AT Medics.

In May 2022, Centene sold off its pharmacy benefit management businesses, Magellan Rx and PANTHERx Rare, for a total of $2.8 billion.

In January 2023, Centene sold Centurion, and in December that year, sold Operose Health to HCRG Care Group.

From Wikipedia’s article on Centene Corporation, shared under CC BY-SA 4.0.8

Leadership

Who has led Centene Corporation, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (64)

Subsidiaries and ownership

Subsidiaries

Also consolidated

Subsidiaries (Exhibit 21)

  • Bankers Reserve Life Insurance Company of Wisconsin, a Wisconsin corporation9
  • Human Affairs International of California, a California corporation9

From Wikidata.1 Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record. The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. Jul 2021Circle Health Group became a subsidiary1

Timeline

  1. Oct 8, 20268-K Other events98
  2. Sep 16, 20268-K Regulation FD disclosure99
  3. Aug 17, 20268-K Executive or director change; Regulation FD disclosure100
  4. Jul 29, 20268-K Other events101
  5. Jul 28, 20268-K Results of operations; Executive or director change; Regulation FD disclosure102
  6. Jun 22, 20268-K Executive or director change; Regulation FD disclosure103
  7. May 15, 20268-K Executive or director change; Shareholder vote104
  8. Apr 28, 20268-K Results of operations105
  9. Mar 24, 20268-K Executive or director change106
  10. Mar 10, 20268-K Regulation FD disclosure; Other events107
  11. Feb 23, 20268-K Regulation FD disclosure108
  12. Feb 6, 20268-K Results of operations109
  13. Mar 2022New chief executive Sarah London becomes CEO1
  14. May 1996New chief executive Michael F. Neidorff becomes CEO1
  15. 1984Founded Founded1

Calendar

Coming up

  1. Oct 27, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.50 a share, on Oct 29, 2025.110

When it reported results

  1. Jul 28, 2026Reported quarterly or annual results102
  2. Apr 28, 2026Reported quarterly or annual results105
  3. Feb 6, 2026Reported quarterly or annual results109
  4. Oct 29, 2025Reported quarterly or annual results111
  5. Jul 25, 2025Reported quarterly or annual results112
  6. Jul 1, 2025Reported quarterly or annual results113
  7. Apr 25, 2025Reported quarterly or annual results114
  8. Feb 4, 2025Reported quarterly or annual results115

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

611 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 80 major events, 436 insider forms, 27 large holders, 48 other. The latest 20:

  1. Oct 15, 20264 EDGAR
  2. Oct 8, 20268-K EDGAR
  3. Sep 30, 20264 EDGAR
  4. Sep 30, 20264 EDGAR
  5. Sep 30, 20264 EDGAR
  6. Sep 30, 20264 EDGAR
  7. Sep 30, 20264 EDGAR
  8. Sep 16, 20264 EDGAR
  9. Sep 16, 20268-K EDGAR
  10. Aug 27, 20264 EDGAR
  11. Aug 26, 2026144 EDGAR
  12. Aug 26, 2026144 EDGAR
  13. Aug 19, 20264 EDGAR
  14. Aug 18, 2026144 EDGAR
  15. Aug 17, 20268-K EDGAR
  16. Aug 5, 2026144 EDGAR
  17. Jul 29, 20268-K EDGAR
  18. Jul 28, 20264 EDGAR
  19. Jul 28, 20263 EDGAR
  20. Jul 28, 20268-K EDGAR

The 611 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

49 open-market trades by officers, directors and large owners since October 2021: 17 buys and 32 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026KOSTER CHRISTOPHERSecretary & General CounselSale56,500$66.90$3.8MForm 4
Aug 18, 2026KOSTER CHRISTOPHERSecretary & General CounselSale47,603$65.36$3.1MForm 4
Jun 10, 2026Burdick Kenneth ADirectorSale80,000$64.55$5.2MForm 4
Dec 4, 2025Burdick Kenneth ADirectorSale32,796$39.00$1.3MForm 4
Dec 3, 2025Burdick Kenneth ADirectorSale33,211$39.04$1.3MForm 4
Aug 8, 2025LONDON SARAHChief Executive OfficerBuy19,230$25.50$490.4KForm 4
Jul 28, 2025Samuels Theodore R. IIDirectorBuy9,000$27.62$248.6KForm 4
Dec 18, 2024Greco ThomasDirectorBuy17,000$59.75$1.0MForm 4
Dec 16, 2024Dallas H JamesDirectorBuy1,693$59.01$99.9KForm 4
Dec 16, 2024BLUME JESSICA L.DirectorBuy250$59.48$14.9KForm 4
Dec 16, 2024COUGHLIN CHRISTOPHER JDirectorBuy10,000$59.44$594.4KForm 4
Dec 13, 2024Samuels Theodore R. IIDirectorBuy5,000$58.86$294.3KForm 4
Nov 13, 2024Asher Andrew LynnChief Financial OfficerBuy17,200$58.14$1.0MForm 4
Nov 8, 2024LONDON SARAHChief Executive OfficerBuy4,117$60.80$250.3KForm 4
May 14, 2024COUGHLIN CHRISTOPHER JDirectorSale878$76.75$67.4KForm 4
May 13, 2024FASOLA KENNETH JPresidentSale8,000$77.62$621.0KForm 4
Feb 13, 2024Robinson Lori JeanDirectorSale10,000$77.41$774.1KForm 4
Feb 7, 2024FASOLA KENNETH JPresidentSale12,000$75.07$900.8KForm 4
Apr 27, 2023Robinson Lori JeanDirectorSale1,400$66.59$93.2KForm 4
Mar 17, 2023LONDON SARAHChief Executive OfficerBuy30,000$62.60$1.9MForm 4

All 49 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Sarah M. London$1.5M$19.5M125
2025Andrew L. Asher$1.2M$16.1M125
2025Christopher A. Koster$768.3K$6.5M125
2025Susan R. Smith$718.3K$4.9M125
2025Tanya McNally$654.8K$3.2M125
2024Chief Executive Officer$1.4M$20.6M125
2024Chief Financial Officer$1.0M$11.2M125
2024Secretary and General Counsel$750.0K$5.1M125
2024Chief Operating Officer$696.2K$3.5M125
2023Chief Executive Officer$1.4M$18.6M125
2023Chief Financial Officer$1.0M$9.9M125
2023Secretary and General Counsel$750.0K$4.8M125

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.41,446,046$2.7B0.0%+1,623,647
Vanguard Capital Management LLC31,478,140$2.0B0.0%+244,075
Aqr Capital Management LLC28,678,701$1.8B0.6%−4,935,086
Vanguard Portfolio Management LLC22,352,704$1.4B0.1%+723,167
State Street Corp21,965,370$1.4B0.0%+319,242
Geode Capital Management, LLC13,309,729$854.0M0.0%+322,217
Wellington Management Group Llp13,301,215$853.8M0.1%+10,757,914
Ameriprise Financial Inc12,419,397$798.2M0.2%+2,291,199
Invesco Ltd.11,179,844$717.6M0.1%+563,673
Harris Associates L P11,124,640$714.1M1.0%−2,969,891
Morgan Stanley10,051,700$645.2M0.0%+171,464
Norges Bank7,651,758$491.2M0.0%New
Arrowstreet Capital, Limited Partnership7,452,257$478.4M0.2%+682,492
Assenagon Asset Management S.A.7,432,058$477.1M0.3%+3,606,783
Charles Schwab Investment Management Inc6,975,962$447.8M0.1%+78,350
Goldman Sachs Group Inc6,359,176$408.2M0.0%+785,632
Two Sigma Investments, LP6,348,038$407.5M0.3%−395,908
Victory Capital Management Inc5,884,626$377.7M0.2%+2,912,366
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC5,517,580$354.2M0.1%+608,249
D. E. Shaw & Co., Inc.5,213,422$334.6M0.2%−2,314,755
Northern Trust Corp4,930,603$316.5M0.0%−36,465
Deerfield Management Company, L.P.4,901,000$314.6M3.9%−1,016,091
Bank Of America Corp /de/4,451,054$285.7M0.0%+603,839
Deutsche Bank Ag\4,008,084$257.3M0.1%−785,078
Jane Street Group, LLC3,818,742$245.1M0.2%−3,104,291

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

48 trades disclosed by members of Congress, the latest 25. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Aug 18, 2025Tim MooreRepublican, HouseSale$100,001 - $250,000−118.6%Report
Aug 8, 2025Julia LetlowRepublican, HouseSale$1,001 - $15,000−149.1%Report
Aug 8, 2025Tim MooreRepublican, HouseBuy$1,001 - $15,000+149.1%Report
Aug 7, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000+151.7%Report
Aug 5, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+144.2%Report
Jul 30, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000+146.5%Report
Jul 29, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000+149.4%Report
Jul 22, 2025Tim MooreRepublican, HouseBuy$1,001 - $15,000+125.2%Report
Jul 21, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000+129.4%Report
Jul 18, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000+124.5%Report
Jul 14, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000+102.2%Report
May 30, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseSale$1,001 - $15,000+8.4%Report
May 15, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+15.6%Report
May 12, 2025Jefferson ShreveRepublican, HouseSale$15,001 - $50,000+22.4%Report
Apr 29, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−22.5%Report
Apr 14, 2025Julia LetlowRepublican, HouseBuy$1,001 - $15,000−33.4%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000−44.6%Report
Mar 31, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseSale$1,001 - $15,000+24.1%Report
Mar 5, 2025Jefferson ShreveRepublican, HouseBuy$15,001 - $50,000−15.1%Report
Oct 29, 2024Val T. HoyleDemocratic, HouseBuy$1,001 - $15,000−18.6%Report
Jul 2, 2024Kathy Manning, HouseBuy$1,001 - $15,000−36.1%Report
Jul 2, 2024Kathy Manning, HouseBuy$1,001 - $15,000−36.1%Report
Jul 12, 2023Daniel S. GoldmanDemocratic, HouseSale$15,001 - $50,000+64.6%Report
Jun 15, 2023Earl Blumenauer, HouseSale$1,001 - $15,000+69.8%Report
Apr 28, 2023Kathy Manning, HouseBuy$1,001 - $15,000−85.2%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Centene Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCENTENE CORP2
  • CIK0001071739
  • Employer ID (EIN)42-140631719
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inDelaware19
  • Fiscal year endsDecember 312
  • Industry code (SIC)6324 Hospital & Medical Service Plans2
  • SEC reviewing officeOffice of Finance, Division of Corporation Finance2
  • Business address7700 Forsyth Blvd., St Louis, MO 631052
  • Phone31472544772
  • Shares outstanding493,995,000 as of Jul 24, 202617
  • Public float$26.7B as of Jun 30, 202519
  • AuditorKPMG LLP, St. Louis, MO PCAOB ID 185; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceOct 9, 20012
  • Filings3,263 in all: 4 (2,171), 8-K (387), SC 13G/A (96), 10-Q (74), 3 (68), 425 (68), SC 13G (44), 5 (38)2
    All 51 form types

    DEF 14A (28), DEFA14A (25), 10-K (24), 424B5 (19), CORRESP (18), CT ORDER (18), 144 (17), 4/A (16), UPLOAD (15), S-8 (12), S-3ASR (11), ARS (10), FWP (10), 424B3 (8), 8-K/A (8), 424B2 (7), PRE 14A (7), S-4/A (7), EFFECT (5), S-4 (5), SCHEDULE 13G/A (5), PX14A6G (4), S-1/A (4), S-3/A (4), SCHEDULE 13G (4), 424B7 (3), S-3 (3), 10-Q/A (2), 3/A (2), 8-A12B/A (2), S-1 (2), 10-K/A (1), 10-K405 (1), 144/A (1), 424B1 (1), 424B4 (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), CERTNYS (1), D (1), DEFR14A (1), DFAN14A (1)

  • Latest filingsAnnual report (10-K) Feb 17, 2026
    Quarterly report (10-Q) Jul 28, 2026
    Proxy statement (DEF 14A) Mar 26, 2026
    Latest 8-K (8-K) Oct 8, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 Par ValueCNCNew York Stock Exchange

From the cover page of the 10-K filed Feb 17, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Centene Corporation names in Item 1A of its 10-K filed Feb 17, 2026: 34 risks under these headings, as written.19

  • Risks Relating to Our Business
  • Failure to timely and effectively identify and mitigate medical cost trends and receive adequate rate adjustments to account for increased acuity could have a material adverse effect on our results of operations, financial condition and cash flows.
  • Any failure to adequately and timely price or anticipate demand for products offered, anticipate changes to the competitive landscape or any reduction in products offered for Medicare and in the Health Insurance Marketplace may have a material adverse effect on our results of operations, financial condition and cash flows.
  • Our Medicare programs are subject to a variety of unique risks that could adversely impact our financial results.
  • Risk-adjustment payment systems make our revenue and results of operations more difficult to estimate and could result in retroactive adjustments that have a material adverse effect on our results of operations, financial condition and cash flows.
  • If we are not successful in procuring new government contracts or renewing existing government contracts, or if we receive an adverse finding or review resulting from an audit or investigation, our business may be adversely affected.
  • We derive a portion of our cash flow and gross margin from our PDP operations, for which we submit annual bids for participation. The results of our bids and the design of the risk-sharing program could have a material adverse effect on our results of operations, financial condition and cash flows.
  • Increases in our pharmaceutical costs could have a material adverse effect on the level of our medical costs and our results of operations.
  • Ineffectiveness of state-operated systems and subcontractors could adversely affect our business.
  • Our encounter data may be inaccurate or incomplete, which could have a material adverse effect on our results of operations, financial condition and cash flows and ability to bid for, and continue to participate in, certain programs.
  • If state regulators do not approve payments of dividends and distributions by our subsidiaries to us, we may not have sufficient funds to implement our business strategy.
  • We derive a significant portion of our premium revenues from operations in a number of states, and our results of operations, financial condition or cash flows could be materially adversely affected by a decrease in premium revenues or profitability in any one of those states.
The other 23 risks
  • Competition may limit our ability to increase penetration of the markets that we serve.
  • We operate in a highly competitive, dynamic and rapidly evolving industry and our failure to adapt could negatively impact our business.
  • If we are unable to maintain relationships with our provider networks and timely update our provider directories, our profitability may be materially adversely affected.
  • If our third-party vendors fail to meet their contractual obligations to us or fail to comply with applicable laws or regulations, our results of operations may be adversely affected and we may be exposed to brand and reputational harm, litigation and/or regulatory action.
  • If we or our third-party vendors are unable to integrate and manage information systems and networks effectively, our operations could be disrupted.
  • A failure in or breach of our operational or security systems, networks or infrastructure, or those of third-party vendors with which we do business, including as a result of cyber-attacks and other data security incidents, could have a material adverse effect on our business.
  • We may be unable to attract, retain or effectively manage the succession of key personnel.
  • An impairment charge with respect to our recorded goodwill, intangible assets and real estate portfolio could have a material impact on our results of operations and shareholders' equity.
  • Risks Relating to Regulatory and Legal Matters
  • Reductions or delays in funding of, changes to eligibility requirements for, government-sponsored healthcare programs in which we participate, and any inability on our part to effectively adapt to changes to these programs could have a material adverse effect on our results of operations, financial condition and cash flows.
  • Significant changes to the ACA and the other government-sponsored healthcare programs in which we participate could materially and adversely affect our results of operations, financial condition, and cash flows.
  • Negative public perception of the managed care industry, including industry practices, could adversely affect our business, operating results, cash flows and prospects.
  • Our business activities are highly regulated and new laws or regulations or changes in existing laws or regulations or their enforcement or application could force us to change how we operate and could harm our reputation and business.
  • Our ability to provide services and support to manage our members' pharmacy benefits face regulatory risks and uncertainties which could materially and adversely affect our results of operations, financial condition and cash flows.
  • We have been and may from time to time become involved in costly and time-consuming litigation and other regulatory proceedings, which require significant attention from our management and could adversely affect our business.
  • If we fail to comply with applicable data privacy and security laws, regulations, rules, standards and contractual obligations, including with respect to third-party vendors that utilize sensitive personal information on our behalf, our business, reputation, results of operations, financial condition and cash flows could be materially and adversely affected.
  • If we fail to comply with the extensive federal and state fraud, waste and abuse laws, our business, reputation, results of operations, financial condition and cash flows could be materially and adversely affected.
  • We might be adversely impacted by tax legislation or challenges to our tax positions.
  • Risks Relating to Conditions in the Financial Markets and Economy
  • Our investment portfolio may suffer losses which could materially and adversely affect our results of operations or liquidity.
  • Adverse credit market conditions may have a material adverse effect on our liquidity or our ability to obtain credit on acceptable terms.
  • We have substantial indebtedness outstanding and may incur additional indebtedness in the future. Such indebtedness could reduce our agility and may adversely affect our financial condition.
  • Risks Associated with Mergers, Acquisitions, and Divestitures
  • Our business and results of operations may be materially adversely affected if we fail to manage and complete divestitures.
  • Previous or future acquisitions may not perform as expected and we may not realize the financial results expected from acquisitions or divestitures.
  • We may be unable to successfully integrate our existing business with acquired businesses and realize the anticipated benefits of such acquisitions.

Legal proceedings

A description of the legal proceedings to which we and our subsidiaries are a party is contained in Note 17. Contingencies to the consolidated financial statements included in Part II of this Annual Report on Form 10-K, and is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceCNC quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
    Wikidata and SEC EDGARChris Coughlin, Board member
  77. 77
    Wikidata and SEC EDGARKen Burdick, Board member
  78. 78
    Wikidata and SEC EDGARWayne DeVeydt, Board member
  79. 79
  80. 80
  81. 81
  82. 82
    Wikidata and SEC EDGARSarah London, Board member
  83. 83
    Wikidata and SEC EDGARBill Trubeck, Board member
  84. 84
    Wikidata and SEC EDGARJames Dallas, Board member
  85. 85
    Wikidata and SEC EDGARLori Robinson, Board member
  86. 86
    Wikidata and SEC EDGARJessica Blume, Board member
  87. 87
  88. 88
    Wikidata and SEC EDGAROrlando Ayala, Board member
  89. 89
  90. 90
  91. 91
    Wikidata and SEC EDGARFrederick Eppinger, Board member
  92. 92
    Wikidata and SEC EDGARDick Gephardt, Board member
  93. 93
    Wikidata and SEC EDGARTommy Thompson, Board member
  94. 94
    Wikidata and SEC EDGARJohn Roberts, Board member
  95. 95
    Wikidata and SEC EDGARRobert Ditmore, Board member
  96. 96
  97. 97
  98. 98
    SEC EDGAROther events
  99. 99
  100. 100
  101. 101
    SEC EDGAROther events
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112
  113. 113
  114. 114
  115. 115
  116. 116
  117. 117
  118. 118
  119. 119
  120. 120
  121. 121
  122. 122
  123. 123
  124. 124
  125. 125